<DOC>
	<DOCNO>NCT01975142</DOCNO>
	<brief_summary>Patients metastatic breast cancer consider HER2 negative screen HER2-amplified circulate tumor cell . If least HER2-amplified circulate tumor cell detect , patient treat Trastuzumab - Emtansine ( T-DM1 ) single arm phase II adaptive design .</brief_summary>
	<brief_title>Validity HER2-amplified Circulating Tumor Cells Select Metastatic Breast Cancer Considered HER2-negative Trastuzumab-emtansine ( T-DM1 ) Treatment .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Inclusion criterion screen : Breast adenocarcinoma consider HER2negative primary tumour unknown status HER2 A least one metastatic site and/or inoperable locoregional relapse Measurable disease ( RECIST v1.1 ) Age 18 75 year Performance status 02 Efficient contraceptive nonmenopause woman Inclusion criterion treatment : At least 1 ( Cohort `` L `` ) 3 ( cohort `` H `` ) HER2 amplify CTC Performance status 02 Adequate cardiac function Adequate hematological biochemical blood test Life expectancy le 3 month Previous history stage III IV invasive cancer Male breast cancer Uncontrolled brain metastasis Significant cumulate exposure anthracyclines Current previous significant history cardiovascular/pulmonary disease Previous use trastuzumab</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Primary tumor HER2 negative</keyword>
	<keyword>CTC HER2 positive</keyword>
</DOC>